Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity

References

• Carson DA, Nobori T, Kajander EO, Carrera CJ, Kubota M, Yamanaka H. Methylthioadenosine (MeSAdo) phosphorylase deficiency in malignancy. Adv Exp Med Biol 1988; 250:179 - 185
   PubMedGoogle Scholar
• Kindler HL, Burris HA III, Sandler AB, Oliff IA. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs 2009; 27:75 - 81
   PubMed Web of Science ®Google Scholar
• Chen ZH, Zhang H, Savarese TM. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase and the alpha and beta-interferons in human pancreatic cell carcinoma cell lines and its implications for chemotherapy. Cancer Res 1996; 56:1083 - 1090
   PubMed Web of Science ®Google Scholar
• Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003; 9:2108 - 2113
   PubMed Web of Science ®Google Scholar
• Hustinx SR, Hruban RH, Leoni LM, Iacobuzio-Donahue C, Cameron JL, Yeo CJ, et al. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in peri-ampullary cancer: a potential new target for chemotherapy. Cancer Biol Ther 2005; 4:83 - 86
   PubMedGoogle Scholar
• Watanabe F, Takao M, Inoue K, Nishioka J, Nobori T, Shiraishi T, et al. Immunohistochemical diagnosis of methylthioadenosine phosphorylase (MTAP) deficiency in non-small cell lung cancer. Lung Cancer 2009; 63:39 - 44
   PubMed Web of Science ®Google Scholar
• García-Castellano JM, Villanueva A, Healey JH, Sowers R, Cordon-Cardo C, Huvos A, et al. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 2002; 8:782 - 787
   PubMed Web of Science ®Google Scholar
• Miyazaki S, Nihioka J, Shiraishi T, Matsumine A, Uchida A, Nobori T. Methylthioadenosine phosphorylase deficiency in Japanese osteosarcoma patients. Int J Oncol 2007; 5:1069 - 1076
   Google Scholar
• Chow WA, Bedell V, Gaytan P, Borden E, Goldblum J, Hicks D, et al. Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional sarcomas. Cancer Genet Cytogenet 2006; 166:95 - 100
   PubMed Web of Science ®Google Scholar
• Li W, Su D, Mizobuchi H, Martin DS, Gu B, Gorlick R, et al. Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. Oncol Res 2004; 14:373 - 379
   PubMed Web of Science ®Google Scholar
• Nobori T, Karras JG, Della Ragione F, Waltz TA, Chen PP, et al. Absence of methylthioadenosine phosphorylase in human gliomas. Cancer Res 1991; 51:3193 - 3197
   PubMed Web of Science ®Google Scholar
• Huang HY, Li SH, Yu SC, Chou FF, Tzeng CC, Hu TH, et al. Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors. Clin Cancer Res 2009; 15:6963 - 6972
   PubMed Web of Science ®Google Scholar
• Wong YF, Chung TK, Cheung TH, Nobori T, Chang AM. MTAP gene deletion in endometrial cancer. Gynecol Obstet Invest 1998; 45:272 - 276
   PubMed Web of Science ®Google Scholar
• Powell EL, Leoni LM, Canto MI, Forastiere AA, Iocobuzio-Donahue CA, Wang JS, et al. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications. Am J Surg Pathol 2005; 29:1497 - 1504
   PubMed Web of Science ®Google Scholar
• Sommer J, Itani DM, Homlar KC, Forastiere AA, Iocobuzio-Donahue CA, Wang JS, et al. Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential targets in chordoma. J Pathol 2010; 220:608 - 617
   PubMed Web of Science ®Google Scholar
• Karikari CA, Mullendore M, Eshleman JR, Argani P, Leoni LM, Chattopadhyay S, et al. Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. Mol Cancer Ther 2005; 4:1860 - 1866
   PubMed Web of Science ®Google Scholar
• Behrmann I, Wallner S, Komyod W, Heinrich PC, Schuierer M, Buettner R, et al. Characterization of methylthioadenosine phosphorylase expression in malignant melanoma. Am J Pathol 2003; 163:683 - 690
   PubMed Web of Science ®Google Scholar
• Schmid M, Malicki D, Nobori T, Rosenbach MD, Campbell K, Carson DA, et al. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene 1998; 17:2669 - 2675
   PubMed Web of Science ®Google Scholar
• Ishii M, Nakazawa K, Wada H, Nishioka J, Nakatani K, Yamada Y, et al. Methylthioadenosine phosphorylase gene is silenced by promoter hypermethylation in human lymphoma cell line DHL-9: another mechanism of enzyme deficiency. Int J Oncol 2005; 26:985 - 991
   PubMed Web of Science ®Google Scholar
• Chen ZH, Olopade OI, Savarese TM. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP-malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis. Mol Pharmacol 1997; 52:903 - 911
   PubMed Web of Science ®Google Scholar
• Tisdale MJ. Methionine synthesis from 5′-methylthioadenosine by tumour cells. Biochem Pharmacol 1983; 32:2915 - 2920
   PubMed Web of Science ®Google Scholar
• Harasawa H, Yamada Y, Kudoh M, Sugahara K, Soda H, Hirakata Y, et al. Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T-cell leukemia (ATL). Leukemia 2002; 16:1799 - 1807
   PubMed Web of Science ®Google Scholar
• M'Soka TJ, Nishioka J, Taga A, Kato K, Kawasaki H, Yamada Y, et al. Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T-cell acute lymphoblastic leukemia by real time quantitative PCR assay. Leukemia 2000; 14:935 - 940
   PubMed Web of Science ®Google Scholar
• Traweek ST, Riscoe MK, Ferno AJ, Braziel RM, Magenis RE, Fitchen JH. Methylthioadenosine phosphorylase deficiency in acute leukemia: pathologic, cytogenetic and clinical features. Blood 1988; 71:1568 - 1573
   PubMed Web of Science ®Google Scholar
• Hori Y, Hori H, Yamada Y, Carrera CJ, Tomonaga M, Kamihira S, et al. The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4A gene in acute type adult T-cell leukemia. Int J Cancer 1998; 75:51 - 56
   PubMed Web of Science ®Google Scholar
• Dreyling MH, Roulston D, Bohlander SK, Vardiman J, Olopade OI. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large cell lymphoma. Genes Chromosomes Cancer 1998; 22:72 - 78
   PubMed Web of Science ®Google Scholar
• Mirebeau D, Acquaviva C, Suciu S, Bertin R, Dastugue N, Robert A, et al. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica 2006; 91:881 - 885
   PubMed Web of Science ®Google Scholar
• Marcé S, Balague O, Colomo L, Martinez A, Holler S, Villamor N, et al. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. Clin Cancer Res 2006; 12:3754 - 3761
   PubMed Web of Science ®Google Scholar
• Kadariya Y, Yin B, Tang B, Shinton SA, Quinlivan EP, Hua X, et al. Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma. Cancer Res 2009; 69:5961 - 5969
   PubMed Web of Science ®Google Scholar
• Vieira de Oliveira SF, Oliveira MM, Urban CA, de Lima RS, Cavalli IJ, Ribeiro EM. Lack of association between LOH in the 9p region and clinicopathologic parameters in primary breast cancer. Cancer Genet Cytogenet 2010; 200:23 - 27
   PubMed Web of Science ®Google Scholar
• Hori H, Tran P, Carrera CJ, Hori Y, Rosenbach MD, Carson DA, et al. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res 1996; 56:5653 - 5658
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboximide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985; 82:4881 - 4885
   PubMed Web of Science ®Google Scholar
• Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273:1109 - 1111
   PubMed Web of Science ®Google Scholar
• Rubin J, Hineman V, Moertel CG, Schutt AJ, Hahn RG. A phase II clinical trial of L-alanosine in advanced large bowel carcinoma. Am J Clin Oncol 1983; 6:191 - 193
   PubMed Web of Science ®Google Scholar
• Creagan ET, Long HJ, Ahmann DL, Green SJ. Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma. Am J Clin Oncol 1984; 7:543 - 544
   PubMed Web of Science ®Google Scholar
• Creagan ET, Schutt AJ, Ingle JN, O'Fallon JR. Phase II clinical trial of L-alanosine in advanced upper aerodigestive cancer. Cancer Treat Rep 1983; 67:1047
   PubMedGoogle Scholar
• Von Hoff DD, Green SJ, Neidhart JA, Fabian C, Budd T, Boyd JF, et al. Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group Study. Invest New Drugs 1991; 9:87 - 88
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms and clinical applications. Mol Cancer Therapy 2007; 6:404 - 417
   PubMed Web of Science ®Google Scholar
• Tan CT, Wollner N, Trippett T, Goker E, Tong WP, Kheradpour A, et al. Pharmacologic-guided trial of sequential methotrexate and thioguanine in children with advanced malignancies. J Clin Oncol 1994; 12:1955 - 1962
   PubMed Web of Science ®Google Scholar
• Subhi AL, Tang B, Balsara BR, Altomare DA, Testa JR, Cooper HS, et al. Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin Cancer Res 2004; 10:7290 - 7296
   PubMed Web of Science ®Google Scholar
• Simile MM, Banni S, Angioni E, Carta G, De Miglio MR, Muroni MR, et al. 5′-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. J Hepatol 2001; 34:386 - 394
   PubMed Web of Science ®Google Scholar
• Wolford RW, Riscoe MK, Johnson L, Ferro AJ, Fitchen JH. Effect of 5′-methylthioadenosine (a naturally occurring nucleoside) on murine hematopoiesis. Exp Hematol 1984; 12:867 - 871
   PubMed Web of Science ®Google Scholar
• Stramentinoli G, Gennari F. Adenosine derivatives of anti-inflammatory and analgesic activity, and therapeutic compositions which contain them as their active principle US patent 4454122 1984;
   Google Scholar
• Moratti E. Pharmaceutical compositions containing 5′-deoxy-5′-methylthioadenosine S-adenosylmethionine and their salts for reducing seborrhea US patent 5753213 1998;
   Google Scholar
• Moreno B, Hevia H, Santamaria M, Sepulcre J, Munoz J, Garcia-Trevijano ER, et al. Methylthioadenosine reverses brain autoimmune disease. Ann Neurol 2006; 60:323 - 334
   PubMed Web of Science ®Google Scholar
• Andreu-Pérez P, Hernandez-Losa J, Moliné T, Gil R, Grueso J, Pujol A, et al. Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth. BMC Cancer 2010; 10:265
   PubMed Web of Science ®Google Scholar
• Li TW, Zhang Q, Oh P, Xia M, Chen H, Bemanian S, et al. S-Adenosylmethionine and methylthioadenosine inhibit cellular FLICE inhibitory protein expression and induce apoptosis in colon cancer cells. Mol Pharmacol 2009; 76:192 - 200
   PubMed Web of Science ®Google Scholar
• Kamatani N, Nelson-Rees WA, Carson DA. Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. Proc Natl Acad Sci USA 1981; 78:1219 - 1223
   PubMed Web of Science ®Google Scholar
• Lubin M, Lubin A. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PLoS ONE 2009; 4:5735
   Web of Science ®Google Scholar
• Lubin M, Lubin A. Strategy for selective killing of tumors deficient in methylthioadenosine phosphorylase (MTAP): a progress report. Proc Am Assoc Cancer Res 2009; 4:e5735
   Google Scholar
• Clarke DA, Hamilton LD, Philips FS, Sternberg SS. Effects of thioguanine in mammals. Cancer 1956; 9:1092 - 1101
   PubMed Web of Science ®Google Scholar
• Bertino JR, Johnson-Farley N, Perez RP, Lubin A, Lubin M. Regression of a human T-cell leukemia lacking the methylthioadenosine phosphorylase (MTAP) gene without toxicity of 6-thioguanine (6TG) by pre-treatment with methylthioadenosine. Proc Am Assoc Cancer Res 2010; 5393
   Google Scholar